A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Once-daily Administration Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Once-daily Administration Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
Inclusion Criteria:
Exclusion Criteria:
Springfield, Massachusetts 01107, United States
Mineola, New York 11501, United States
Orangeburg, South Carolina 29118, United States
Mar del Plata, Buenos Aires B7600DHK, Argentina
Essen, 45136, Germany
Shatin, New Territories, Hong Kong SAR, Hong Kong
Shatin, New Territories, Hong Kong SAR, Hong Kong
Lido Camaiore. (Lucca), Lucca 55041, Italy
Kubong Kerian, Kelantan 16150, Malaysia
Lima, Lima Province 27, Peru